Press release
Keros Reinforces Commitment to Maximizing Stockholder Value
Responds to Recent Public Stockholder Communications Urges Stockholders to Protect Their Investment by Voting “FOR” the Company’s Highly Qualified Director
About this update from Keros Therapeutics, Inc.
[{"type":"text","content":"Responds to Recent Public Stockholder Communications Urges Stockholders to Protect Their Investment by Voting “FOR” the Company’s Highly Qualified Director Nominees LEXINGTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”, the “Company” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today issued the following statement in response to the misleading press release issued by ADAR1 Capital Management (“ADAR1”) regarding Keros’ upcoming 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”), currently scheduled for June 4, 2025: The Board is committed to acting in the best interests of the Company and all of its stockholders. In line with this commitment, Keros values the views of its stockholders and has a proactive engagement program in place to ensure that their perspectives are incorporated into the Board’s decision-making process. To that end, feedback gathered from stockholders – including ADAR1 – was considered as the Board determined to undertake a formal review process to evaluate strategic alternatives to maximize stockholder value, led by a strategic committee consisting of independent and disinterested directors (the “Strategic Committee”), as previously announced on April 10, 2025. The Strategic Committee, with the assistance of outside financial and legal advisors, intends to consider a comprehensive range of strategic alternatives, including but not limited to a sale of the Company or other business combination transaction, continued investment in the Company’s pipeline, and/or return of excess capital to stockholders. While the Board evaluates strategic alternatives, Keros’ directors remain highly engaged in developing and overseeing the execution of the Company’s strategy to enhance value for stockholders. Recent strategic initiatives have reinforced our strong cash position and enabled us to fund our clinical programs and operations into 2029 as we continue to develop differentiated product candidates. For example, our exclusive license agreement with Takeda Pharmaceuticals U.S.A., Inc., which secured a $200 million upfront payment and the p...